Another EFPIA warning on Brexit implications for pharma

Just head of UK Prime Minister Theresa May’s decision was announced to postpone the parliamentary vote on the Brexit withdrawal declaration that was due on Tuesday, the European Federation of Pharmaceutical Industries and Associations (EFPIA) today issued another warning about the implications for the pharma industry.

EFPIA director general Nathalie Moll said: “While for most sectors the issues are primarily economic, for the healthcare sector the primary concerns are patient safety and public health. A disorderly exit from the European Union by the UK has very real and tangible consequences for patient safety and public health in both the UK and across Europe. We hope that politicians in the UK take this into consideration during tomorrow’s vote.”